|Bid||234.46 x 100|
|Ask||238.82 x 100|
|Day's range||240.15 - 251.39|
|52-week range||186.98 - 273.87|
|PE ratio (TTM)||310.52|
|Earnings date||27 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||297.25|
Amedisys' (AMED) acquisition of Tenet Healthcare's home health and hospice operations in Arizona might help the company deliver high-quality post-acute services in the key markets.
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and declining HPV sales.
Bio-Rad Laboratories, Inc. , a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2017 on Tuesday, February 27, 2018, following the close of the market.
We are encouraged by Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific.
Integra LifeSciences (IART) witnesses strong global sales within specialty surgical driven by strength in door repair and tissue ablation franchises in Asia Pacific and Europe.
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oritani Financial Corp. (NASDAQ:ORIT), Bio-Rad Laboratories, Inc. (NYSE:BIO), Compass Diversified Holdings (NYSE:CODI), Q2 Holdings, Inc. (NYSE:QTWO), Medpace Holdings, Inc. (NASDAQ:MEDP), and Engility Holdings, Inc. (NYSE:EGL), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that it has received 510 clearance from the U.S.
Becton, Dickinson's (BDX) focus in the Balloon-Angioplasty space is expected to lend the company a competitive edge in the niche MedTech markets.